The Trust is dedicated to supporting our community to manage the emotional and psychological pressures of cystic fibrosis (CF). You can find further information on managing your own mental health or how to support others here.
We recently launched a new project to break down some of the barriers people from Black, Asian and minority ethnic communities can face when it comes to accessing CF clinical trials. In this blog, Loren from our Clinical Trials Accelerator Platform team, shares more about this project, why it’s important, and our ongoing commitment to make sure everybody with CF can live a life unlimited.
The Cystic Fibrosis Trust has been working with NHS England and the UK CF Medical Association (UKCFMA) to support the roll out of home monitoring devices and apps to help people with CF stay well at home and spot health problems early during the coronavirus (COVID-19) pandemic.
This week Vertex will meet with NHS England on Wednesday 25 April to discuss further negotiations around access to precision medicine Orkambi and similar future cystic fibrosis (CF) treatments. Lynsey Beswick, Public Affairs Manager at the Cystic Fibrosis Trust, explains what’s happened since last month’s debate in Parliament and what the next steps are for the campaign.
The European Medicines Agency (EMA) has today given marketing authorisation for new cystic fibrosis (CF) medicine Symkevi. This important milestone means that, if an agreement can be reached between the NHS and the manufacturer, Vertex Pharmaceuticals, the treatment could be available for people with CF in the UK.
We’re proud to announce that the Cystic Fibrosis Trust is funding three new Strategic Research Centres that will begin this autumn. This £2.2m investment over three years will involve 20 researchers from five different countries, who will tackle research priorities such as more effective treatments for lung infections and more effective, tailored treatments to improve lung clearance.
New training and equipment provided by the Trust’s Clinical Trials Accelerator Platform will ensure a wider range of clinical trials are accessible to the UK cystic fibrosis (CF) community.
